2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Language characteristics of picture description task by Hebrew speaking patients with Parkinson’s disease

D. Shpunt, S. Naor, N. Diamant, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich, Y. Manor (Tel Aviv, Israel)

Other · Agora 2 West, Level 2

1:45pm-3:15pm: Long Term Follow Up Following Multidisciplinary Inpatient Rehabilitation for Functional Movement Disorders

A. Kompoliti, C. Hebert, J. Behel, G. Pal, R. Kasi (Chicago, IL, USA)

Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, Y. Thongchuam, T. Boonmongkol, P. Garcia Ruiz (Bangkok, Thailand)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up

A. Antonini, P. Odin, R. Pahwa, J. Aldred, A. Alobaidi, Y. Jalundhwala, P. Kukreja, L. Bergmann, S. Inguva, Y. Bao, K. Chaudhuri (North Chicago, IL, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality

CA. Artusi, R. Balestrino, G. Imbalzano, S. Bortolani, S. Tuttobene, E. Montanaro, M. Zibetti, L. Lopiano (Torino, Italy)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, K. Chaudhuri, T. Henriksen, T. van Laar, D. Lockhart, A. Lees (London, United Kingdom)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea

K. Dashtipour, S. Isaacson, M. Lew, D. Chary, T. Clinch, R. Pahwa (Boca Raton, FL, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic

C. Muniz, S. Baser, R. Ericson, M. Santana Jimenez, C. Bass, F. Middleton (Santo Domingo, Dominican Republic)

Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3

1:45pm-3:15pm: Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01

A. van Laar, R. Richardson, A. Sedkov, E. Fine, K. Bankiewicz, B. Ravina, P. Larson, C. Christine (Pittsburgh, PA, USA)

Gene and Cell-Based Therapies · Les Muses Terrace, Level 3

1:45pm-3:15pm: Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease

I. Wurster, S. Lerche, I. Lachmann, M. Neumann, T. Gasser, K. Brockmann (Tübingen, Germany)

Genetics · Les Muses Terrace, Level 3